Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

Resources for understanding the dangers of drug importation

March 28, 2017

Recap of some of the latest resources on importation.

Read More

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

March 27, 2017

To help ensure patients have affordable access to breakthrough therapies, we need a payment system as innovative as todayâ??s medicines.

Read More

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

March 27, 2017

To help ensure patients have affordable access to breakthrough therapies, we need a payment system as innovative as todayâ??s medicines.

Read More

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

March 27, 2017

To help ensure patients have affordable access to breakthrough therapies, we need a payment system as innovative as todayâ??s medicines.

Read More

Medicare Monday: A discussion on affordability and access to medicines

March 27, 2017

An excerpt of Lori Reilly's piece in Aging Today.

Read More

17 years (and more) of medical discoveries

March 24, 2017

Priscilla's story of receiving a kidney transplant 17 years ago.

Read More

ICYMI: What the experts are saying about importation

March 23, 2017

Importation - FDA commissioners and other stakeholder comments

Read More

Guest Post: The importance of a modern FDA in drug discovery

March 22, 2017

A swift passage of PDUFA VI will maximize the potential of 21st century medicine and ensure that every related decision is in the best interest of patients.

Read More

PhRMA Statement on FDA User Fees

March 22, 2017

PhRMA president and CEO Stephen J. Ubl issued a statement in support of the U.S. Food and Drug Administration’s (FDA) user fee programs the Prescription Drug User Fee Act (PDUFA) VI, Biosimilar User Fee Act (BsUFA) II and the Generic Drug User Fee Act (GDUFA) II.

Read More

PhRMA Statement on NAFTA Tribunal Decision in the Eli Lilly Case

March 21, 2017

PhRMA issued statement on the NAFTA Tribunal Decision in the Eli Lilly Case.

Read More